09:59 AM EST - Zentek Ltd. : Announces that its wholly-owned subsidiary Triera Biosciences Ltd. has prioritized the development of a prophylaxis and therapeutic for highly pathogenic avian influenza ("HPAI") and reports initial test results. Universal aptamer has been selected for influenza virus, including H5N1. Binding affinity of influenza aptamer is better than aptamer used for SARS-CoV-2, which has demonstrated improved protection over leading monoclonal antibodies in animal models Development prioritized given current global HPAI H5N1 outbreak. In vivo testing to begin immediately. Zentek Ltd.
shares V.ZEN are trading up $0.03 at $1.45.
